Общие принципы лучевой терапии 5 page

*

Глава 28. Лучевая терапия злокачественных опухолей мочевых путей и половых органов

Pollack A et al.: Conventional vs. conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 3:4555.

Pollack A, Zagars G: External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Bio Phys 1997; 39:192.

Pollack A, Zagars G, Swanson D: Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors. Int J Radiat Oncol Biol Phys 1994; 30:267.

Pollack A, Zagars GZ: Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996; 14:86.

Prestidge BR, Kaplan I, Bagshaw MA: The clinical significance of a positive post-irradiation prostatic biopsy without distant metastases. Proceedings of the 33rd Annual ASTRO Meeting. Abstract 72. Int J Radiat Oncol Biol Phys 1991; 21 (Suppl 1): 152.

Presti JC et al.: Effect of adjuvant radiation therapy on urodynamic parameters following radical retropubic prostatectomy. Radiat Oncol Invest 1996; 4:192.

Quilty PM, Duncan W: Primary radical radiotherapy for T3 tran­sitional carcinoma of the bladder: An analysis of survival and control. Int J Radiat Oncol Biol Phys 1986; 12:861.

Quilty PM et al.: Results of surgery following radical radiotherapy for invasive bladder cancer. Br J Urol 1986; 58:396.

Radwin H M: Radiotherapy and bladder cancer: A critical review. J U rol 1980; 124:43.

Ragde H et al.: Cancer Ten-year disease free survival after trans-perineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low Gleason grade prostate cancer. Cancer 1998; 83:989.

Reddy EK, Mebust WK, Weigel JW: Iodine-125 implantation in localized prostatic cancer. Endo Hyper-therm Oncol 1990; 6:239.

Rehman J et al.: The timing of adjuvant radiotherapy (RT) after radical prostatectomy and its relationship to pathologic stage and sys­temic recurrence. Annual Meeting of the American Urological Asso­ciation, May 14-19, 1994. J Urol 1994.

Ritter MAet al.: Prostate-specific antigen as predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10:1208.

Roach M, ChinnDM, Holland J: A pilot survey of sexual function and quality of life following 3-D conformal radiotherapy for clinically loca­lized prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35:869.

Roach M: Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate specific antigen (PSA) and Gleason score. J Urol 1993; 150:1923.

Roach M et al.: Bilateral arcs using "averaged beam's eye views": A simplified technique for delivering 3-D based conformal radiotherapy. Med Dosimetry 1994a; 19:159.

Roach M et al.: Defining treatment margins for 3-D based six field conformal (SFC) irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 1994b; 28:267.

Roach M et al.: Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials. J Urol 1999; 161:864.

Roach M et al.: 501 men irradiated for clinically localized prostate cancer (1987—1995): Preliminary analysis of experience at UCSF and affiliated facilities. Int J Radiat Oncol Biol Phys 1996a; 36(Suppl 1):248.

Roach M et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994c; 28:33.

Roach M et al.: Prognostic subgroups predict disease specific survival for men treated with radiotherapy alone on radiation therapy oncology group (RTOG) prostate cancer trials. Proceedings of the American So­ciety of Clinical Oncology, 34th Annual Meeting. Proceedings of the American Society for Clinical Oncology 1998; 17:312a.

Roach M et al.: Radiotherapy (XRT) for high grade (HG) clinically

localized adenocarcinoma of the prostate (CAP). J Urol 1996b; 156:1719.

Roach M et al.: The role of the urethrogram during simulation for

localized prostate cancer. Int J Radiat Oncol Biol Phys 1993a; 25:299.

Roach M et al.: Treatment of 100 consecutive patients by using six-f conformal radiation therapy: Acute and short term toxicity. 1993b; 189(Suppl):183.

Roach M, Pickett B, Phillips TL: An analysis of the advantages as well as the physical and clinical limitations of three-dimensionally (3-D) based co-planar conformal external beam irradiation (XRT) in the treatment of localized prostate cancer. In: Minet P (editor): Three-Dimensional Treat­ment Planning. Liege, 1993.

Roach M, Pickett B, Weil M: The "Critical Volume Tolerance Method" for estimating the limits of dose escalation during three-dimensional con­formal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35:1019.

Roach M, Rosenthal S, Hunter D: 100 consecutive patients treated for clinically localized prostate cancer by six field conformal radiotherapy: Acute toxicity and lessons learned from the UCSF/Davis experience. Radiology 1993; 189:183.

Roach M, Wallner K: Prostate cancer. In: Leibel SA, PhillipsTL(eds): Textbook of Radiation Oncology. Saunders, 1998.

Rogers R et al.: Radiation therapy for the management of biop­sy-proven, local recurrence following radical prostatectomy. J Urol 1998; 160:1748.

Rorth BJ et al. and the Danish Testicular Cancer Group: Surveillance alone versus radiotherapy after orchiectomy for clinical stage I non-seminomatous testicular cancer. J Clin Oncol 1991; 9:1543.

Rorth M: Therapeutic alternatives in clinical stage I non-semino-matous disease. Semin Oncol 1992; 19:190.

Rosenthal SA el al: Immobilization improves the reproducibility of patient positioning during six-field conformal radiation therapy forpros-tate cancer. Int J Radiat Oncol Biol Phys 1993; 27:921.

Rossi CJ et al.: Particle beam radiation therapy in prostate cancer: Is there an advantage? Semin Radiat Oncol 1998; 8:115.

Rubin P, Casarett GW: Clinical Radiation Pathology, vol. 1, p. 423-410. Saunders, 1968.

Rubin P, Constine LS, Williams JP: Late effects of cancer treatment: Radiation and drug toxicity. In: Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, 3rd ed. Lippincott-Raven, 1998.

Russell KJ et al.: Photon versus neutron external beam radiotherapyin the treatment of locally advanced prostate cancer: Results of a rando­mized prospective trial. Int J Radiat Oncol Biol Phys 1994; 28:47.

Russell KJ et al.: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991; 146:1046.

Sagerman RH et al.: External beam irradiation of carcinoma of the penis. Radiology 1984; 152:183.

Sailer SL, Shipley WU, Wang CC: Carcinoma of the female urethral review of results with radiation therapy. J Urol 1988; 140:1.

Sandler H et al.: 3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients. Proceedings of the 35th ASTRO Meeting. Int J Radiat Oncol Biol Phys 1993; 27(Suppl 1):135.

Sandler HM et al.: Dose escalation for stage С (ТЗ) prostate cancel: Minimal rectal toxicity observed using conformal radiotherapy. Radio-ther Oncol 1992; 23:54.

Scardino PT, Wheeler TM: Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results ofpostirradiation prostate biopsy. NCI Monogr 1988; 7:95.

Schellhammer PF et al.: Prostate biopsy after definitive treatmenthy interstitial 125-iodine implant or external beam radiation therapy. J Urol 1987; 37:897.

Schellhammer PF et al.: Prostate specific antigen to determine prog­ression free survival after radiation therapy. Urology 1993; 42:13.

Schild SE et al.: Radiotherapy for isolated increases in serum pros­tate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994; 69:613.

Sell A et al.: Treatment of advanced Bladder cancer category T2.T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy fot residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group, Scand J Urol Nephrol 1991 (Suppl); 138:193.

»

Глава 28. Лучевая терапия злокачественных опухолей мочевых путей и половых органов

Seung SK et al.: External beam radiotherapy in men who would have teen candidates for 1-125 implantation monotherapy. Cancer J Sci Am 1998; 4:168.

Shapiro E, Kinsella TI, Makuch RW: Effects of fractionated irradiation on endocrine aspects of testicular function. J Clin Oncol 1985; 3:1232.

Sharda NN, Kinsella TI, Ritter MA: Adjuvant radiation versus obser­vation: A cost analysis of alternate management schemes in early stage testicular seminoma, J Clin Oncol 1996; 14:2933.

Shipley WU et al.: Advanced prostate cancer: The results of a rando­mized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alo­ne. IntJ Radiat Oncol Biol Phys 1995; 32:3.

Shipley WU et al.: Full-dose irradiation for patients with invasive bladder carcinoma: Clinical and histologic factors prognostic of impro­ved survival. J Urol 1985; 134:679.

Shipley WU et al.: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preser­vation by combined radiation therapy and chemotherapy: Initial results of radiation therapy oncology group 89-03. J Clin Oncol 1998; 16:3576.

Shipley WU et al.: The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer 1987; 60:514.

Shultheiss ТЕ, Hanks GE, Hunt MA: Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32:643.

Sklar G: Combined anti-tumor effect of suramin plus irradiation in hu­man prostate cancer cells. The role of apoptosis. J Urol 1993; 150:1526.

Slack NH, Brass IDJ, Prout GR: Five year follow-up of results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977; 9:393.

Smit WG et al.: Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990; 18:23.

Soffen EM et al.: Decreased acute morbidity with conformal static field radiation therapy treatment of early prostate cancer as compared to non-conformal techniques. Proceedings of the 33rd Annual ASTRO Meeting. Abstract 71. Int J Radiat Oncol Biol Phys 1991; 21 (Suppl 1): 152. SrinivasV, KhanSA: Male urethral cancer: A review. Int Urol Nephrol 1988; 20:61.

Stamey TX, Ferrari MK, Schmid HS: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply in­creasing values characterize 80% of patients. J Urol 1993; 50:1856.

Stein A et al.: Adjuvant radiotherapy in patients with post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 1992a; 39:59.

Stein A et al.: Prostate specific antigen levels after radical prostatec­tomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992b; 147:942.

Sultanem К et al.: Para-aortic irradiation only appears to be adequate treatment for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 1998; 40:455.

Tait DM et al.: Acute toxicity in pelvic radiotherapy; A randomized trial of conformal versus conventional treatment. Radiother Oncol 1997; 42:121. Ten Haken RK et al.: Boost treatment of the prostate using shaped, fixed fields. IntJ Radiat Oncol Biol Phys 1989; 6:193. Ten Haken RK et al.: Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int I Radiat Oncol Biol Phys 1991; 20:1317.

Tester Wet al.: Neoadjuvant combined modality program with selec­tive organ preservation for invasive bladder cancer: Results of Radiation TherapyOncologyGroupphaseIItrial8802.JClin Oncol 1996; 14:119. Thames HD, Peters LJ, Ang KK: Time-dose considerations for nor­mal tissue tolerance. In: VaethJM, MeyerJL(eds): Radiation Tolerance ofNormalTissues,vo\.23,p. 113-130. Karger, 1989. Thomas GM: Consensus statement on the investigation and manage­ment of testicular seminoma. In: Newling DW, Jones WG (eds): Prostate Сжег and Testicular Cancer (EORTC Genitourinary Group Mono­graph?). Wiley-Liss, 1990.

Thomas GM: Controversies in the management of testicular semi­noma. Cancer 1985; 55:2298.

Thomas GM, Williams SD: Testis. In: Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, 3rd ed. Lippincott-Raven, 1998.

Trapasso JG et al.: The incidence and significance of detectable levels of serum after radical prostatectomy. J Urol 1994; 152:1821.

Van der Werf-Messing ВНР et al.: Cancer of the urinary bladder category T2, T3 (NxMo) treated by interstitial radium implant: Second report. Int J Radiat Oncol Biol Phys 1983; 9:481.

Van der Werf-Messing ВНР et al.: Carcinoma of the urinary bladder (category TINxMO) treated either by radium implant or transurethral resection only. IntJ Radiat Oncol Biol Phys 1981; 7:299.

Vanuystel L el al.: Radiotherapy in multiple fractions per day for prostatic carcinoma: Late complications. Int J Radiat Oncol Biol Phys 1986; 12:1589.

Vijayakumar S et al.: Acute toxicity during external-beam radiothe­rapy for localized prostate cancer: Comparison of different techniques. Int J Radiat Oncol Biol Phys 1993; 25:359.

Vijayakumar S et al.: Beams eye view-based photon radiotherapy. Int J Radiat Oncol Bio! Phys 1991; 21:1575.

VogesGEetal.: Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992; 69:520.

Wallner Ketal.: PSA response aftertransperineal 1-125 prostate im­plantation. Int J Radiat Oncol Biol Phys 1993; 27(Suppl 1):228.

Warde P et al.: Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997; 157:1705.

Warde P et al.: Stage 1 testicular seminoma: Results of adjuvant irra­diation and surveillance. J Clin Oncol 1995; 13:2255.

Warde P, Gospodarowicz M K: N ew approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder. World J Urol 1997; 15:125.

Warde P, Gospodarowicz M: Management of stage II seminoma. J Clin Oncol 1998; 16:290.

Wu JJ et al.: The efficacy of postprostatectomy radiotherapy in pa­tients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 32:317.

Zagars GK, Babaian RJ: The role of radiation in stage II testicular seminoma. IntJ Radiat Oncol Biol Phys 1987; 13:163.

Zagars GK, Pollack A: Radiation therapy for TI and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 1995; 45:476.

Zagars GK, von Eschenbach AC: Prostate-specific antigen: An im­portant marker for prostate cancer treated by external beam radiation. Cancer 1993; 72:538.

Zelefsky MJ et al.: Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperianal per­manent iodine-125 implantation for early stage prostate cancer. J Clin Oncol 1999; 17:517.

Zelefsky MJ et al.: Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998; 8:107.

Zietman A et al.: A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluo-rouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998; 160:1673.

Zietman AL el al: The effects of androgen deprivation and radiation therapy on androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 1997; 3:31.

Zietman AL et al.: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from PSA failure. Urology 1993; 42:292.

Zietman AL et al.: Radical prostatectomy for adenocarcinoma of the prostate: The influence of pre-operative and pathologic findings on bio­chemical disease free outcome. Urology 1994; 43:828.

Zietman AL et al.: The treatment of prostate cancer by conventional radiation therapy: An analysis of long term outcome. Int J Radiat Oncol Biol Phys 1995; 32:287.

Zincke H et al.: Long term (15 years) results after radical prostatec­tomy for clinically localized (staged T2c or lower) prostate cancer. J Urol 1994; 152:1850.

*

29 Э. Танаго, Т. Лю